Synonym
R-IMPP Hydrochloride; R IMPP Hydrochloride; RIMPP Hydrochloride; R-IMPP HCl
IUPAC/Chemical Name
(R)-N-(Isoquinolin-1-yl)-3-(4-methoxyphenyl)-N-(piperidin-3-yl)propanamide Hydrochloride
InChi Key
OSIRDWNTKGVIOE-VEIFNGETSA-N
InChi Code
InChI=1S/C24H27N3O2.ClH/c1-29-21-11-8-18(9-12-21)10-13-23(28)27(20-6-4-15-25-17-20)24-22-7-3-2-5-19(22)14-16-26-24;/h2-3,5,7-9,11-12,14,16,20,25H,4,6,10,13,15,17H2,1H3;1H/t20-;/m1./s1
SMILES Code
O=C(N(C1=NC=CC2=C1C=CC=C2)[C@H]3CNCCC3)CCC4=CC=C(OC)C=C4.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
R-IMPP is an inhibitor of PCSK9 secretion, half maximal inhibitory concentration [IC50] = 4.8 μM.
In vitro activity:
In this study, R-IMPP did not decrease PCSK9 transcription or increase PCSK9 degradation, but caused transcript-dependent inhibition of PCSK9 translation. They found that R-IMPP was able to selectively bind to human, but not E. coli, ribosomes.
Reference: Cell Chem Biol. 2016 Nov 17;23(11):1362-1371. https://pubmed.ncbi.nlm.nih.gov/27746128/
In vivo activity:
To be determined
Preparing Stock Solutions
The following data is based on the
product
molecular weight
425.96
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Petersen DN, Hawkins J, Ruangsiriluk W, Stevens KA, Maguire BA, O'Connell TN, Rocke BN, Boehm M, Ruggeri RB, Rolph T, Hepworth D, Loria PM, Carpino PA. A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation. Cell Chem Biol. 2016 Nov 17;23(11):1362-1371. doi: 10.1016/j.chembiol.2016.08.016. Epub 2016 Oct 13. PMID: 27746128.
In vitro protocol:
1. Petersen DN, Hawkins J, Ruangsiriluk W, Stevens KA, Maguire BA, O'Connell TN, Rocke BN, Boehm M, Ruggeri RB, Rolph T, Hepworth D, Loria PM, Carpino PA. A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation. Cell Chem Biol. 2016 Nov 17;23(11):1362-1371. doi: 10.1016/j.chembiol.2016.08.016. Epub 2016 Oct 13. PMID: 27746128.
In vivo protocol:
To be determined
1: Petersen DN, Hawkins J, Ruangsiriluk W, Stevens KA, Maguire BA, O'Connell TN, Rocke BN, Boehm M, Ruggeri RB, Rolph T, Hepworth D, Loria PM, Carpino PA. A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation. Cell Chem Biol. 2016 Nov 17;23(11):1362-1371. doi: 10.1016/j.chembiol.2016.08.016. Epub 2016 Oct 13. PubMed PMID: 27746128.
2: Alannan M, Trézéguet V, Amoêdo ND, Rossignol R, Mahfouf W, Rezvani HR, Dittrich-Domergue F, Moreau P, Lacomme S, Gontier E, Grosset CF, Badran B, Fayyad-Kazan H, Merched AJ. Rewiring Lipid Metabolism by Targeting PCSK9 and HMGCR to Treat Liver Cancer. Cancers (Basel). 2022 Dec 20;15(1):3. doi: 10.3390/cancers15010003. PMID: 36612001; PMCID: PMC9817797.
